NCT04625101 - Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-827104 in Pediatric Subjects With Epileptic Encephalopathy With Continuous Spike-and-Wave During Sleep | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 26, 2021

Primary Completion Date

August 8, 2022

Study Completion Date

October 11, 2022

Conditions

Epileptic EncephalopathyContinuous Spike and Wave During Sleep

Interventions

DRUG

NBI-827104

Triple T-type calcium channel blocker.

DRUG

Placebo

Non-active dosage form.

Trial Locations (15)

4031

Neurocrine Clinical Site, Basel

4293

Neurocrine Clinical Site, Dianalund

8032

Neurocrine Clinical Site, Zurich

19104

Neurocrine Clinical Site, Philadelphia

20010

Neurocrine Clinical Site, Washington D.C.

27710

Neurocrine Clinical Site, Durham

28034

Neurocrine Clinical Site, Madrid

33155

Neurocrine Clinical Site, Miami

44195

Neurocrine Clinical Site, Cleveland

55905

Neurocrine Clinical Site, Rochester

80045

Neurocrine Clinical Site, Aurora

92868

Neurocrine Clinical Site, Orange

T3B 6A8

Neurocrine Clinical Site, Calgary

08950

Neurocrine Clinical Site, Barcelona

WC1N 3JH

Neurocrine Clinical Site, London